Highest response rates to TKIs in patients with EGFR-TK mutatio

EGFR is expressed on the cell surface of a substantial percentage of NSCLCs. Initial studies with the EGFR tyrosine kinase inhibitors (TKIs) gefitinib (Iressa) and erlotinib (Tarceva) demonstrated biologic and clinical activity in only a relatively limited subset of lung cancers.[4]

Further investigation demonstrated that the highest response rates to these TKIs were seen in patients with somatic mutations within the EGFR-TK domain, particularly exon 19 deletion, exon 21 L858R, and exon 18 G719X.[5]

By contrast, the exon 20 T790M mutation is associated with acquired resistance to TKI therapy.[6]

http://emedicine.medscape.com/article/1689988-overview

所有跟帖： 

• 能否明言是否有效？引文看起來太難。 -litianxin- ♀ (0 bytes) () 11/11/2014 postreply 11:59:06

• Iressa/Tarceva 對有 EGFR exon 21 突變者有效率高。 -26484915- ♂ (6 bytes) () 11/11/2014 postreply 12:00:41

• 國內建議特羅凱？有效嗎？ -litianxin- ♀ (0 bytes) () 11/11/2014 postreply 12:02:55

• 易瑞沙和特羅凱. 特羅凱= Tarceva -26484915- ♂ (0 bytes) () 11/11/2014 postreply 12:04:44

• 2種藥都是口服藥，沒有必要住院。 -26484915- ♂ (0 bytes) () 11/11/2014 postreply 12:40:00

• 用周邊血檢測的基因突變，而不是活檢，是否準確？ -litianxin- ♀ (0 bytes) () 11/11/2014 postreply 12:09:11

• 血檢說有突變那就是有。血檢說沒有不一定沒有。 -26484915- ♂ (0 bytes) () 11/11/2014 postreply 12:11:50

• 多謝 -litianxin- ♀ (0 bytes) () 11/11/2014 postreply 12:12:58